Search the Newsreel

Persimmon Plc 2026 Q2 - Results - Earnings Call Presentation (OTCMKTS:PSMMY) 2026-08-06

Earnings Flash (IMCR) Immunocore Posts Q2 Loss $0.02 a Share, vs. FactSet Est of $0.02 Loss

Immunocore Holdings plc reported a Q2 loss of $0.02 per share, which aligns with FactSet's estimate. This financial update follows an earlier report of their Q2 revenue reaching $115.9 million, surpassing FactSet's estimate of $110.4 million. The company, a United Kingdom-based biotechnology firm, specializes …

Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss

Immunovant (IMVT) reported a fiscal Q1 loss of $0.75 per share, which is wider than the FactSet estimate of a $0.65 loss per share. The company is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. Its pipeline includes product candidates …

Persimmon improves completion guidance despite ‘challenging’ housing market

Housebuilder Persimmon has said it expects to deliver home completions at the "upper end" of targets, despite a challenging property market. Boss Dean Finch said that "affordability constraints and build cost pressures" are continuing to drag on the industry. However, the company said profits …

ImmuCell (ICCC) Expected to Release Earnings on Thursday

Zimmer Biomet (ZBH) Stock Gains Ground While Margins Tighten

Lyell Immunopharma (LYEL) Earnings Date and Reports 2026 $LYEL

Persimmon (LON:PSN) Posts Earnings Results

Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Revenue Breakdown – FWB:6YG

Immunocore Holdings Plc (FWB:6YG) generated €340.58 million in revenue last year, primarily from its Immunotherapies segment. The United States was the largest geographical contributor, accounting for €218.81 million of the company's revenue. The article highlights the company's top-performing segment and its major market.

Immatics (IMTX) Expected to Release Quarterly Earnings on Wednesday

Immatics (IMTX) is expected to announce its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts forecasting a loss of $0.43 per share and revenue of $11.9 million. The company missed estimates in the prior quarter and currently holds a "Moderate …

ZIMMER BIOMET HOLDINGS, INC. : STIFEL RAISES TARGET PRICE TO $110 FROM $105

Stifel has increased its target price for Zimmer Biomet Holdings, Inc. (ZBH.N) to $110 from $105. This adjustment reflects a change in the financial outlook or valuation assessment by the analyst firm for the medical technology company. The article, sourced from Reuters, reports this …

Earnings Flash (ZBH) Zimmer Biomet Holdings, Inc. Posts Q2 Adjusted EPS $2.07 per Share, Vs. FactSet Est of $2.01

Zimmer Biomet Holdings, Inc. (ZBH) reported strong second-quarter adjusted earnings per share of $2.07, surpassing the FactSet estimate of $2.01. The company's revenue also exceeded expectations, coming in at $1.85 billion against an estimated $1.81 billion. This positive performance indicates a strong financial quarter …

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy

Stifel initiated coverage on Lyell Immunopharma (NASDAQ:LYEL) with a buy rating and a price target of $36.00, citing the potential of its Rondecabtagene autoleucel (Ronde-cel) CAR T-cell therapy. The firm believes Ronde-cel could achieve clinical superiority and regulatory approvals by 2028 and 2030, projecting …

Zimmer Biomet Holdings Inc (ZBH) (Q2 2026) Earnings Call Highlights: Strong Sales Beat and Raised Guidance Amid Strategic Investments

Zimmer Biomet Holdings Inc (ZBH) reported strong Q2 2026 results, exceeding expectations with $2.177 billion in net sales and 4% organic constant currency growth, primarily driven by robust US performance in the hips segment and technology. The company raised its full-year 2026 revenue and …

BTIG Research Reaffirms "Buy" Rating for AC Immune (NASDAQ:ACIU)

Zimmer Biomet (NYSE: ZBH) awards 10,168 RSUs to President, APAC

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) has awarded 10,168 restricted stock units (RSUs) to Chintan Desai, President, APAC. These RSUs represent a contingent right to one share of common stock each, with one-third vesting on August 3rd of 2027, 2028, and 2029. Following this …

Needham reiterates Hold on Zimmer Biomet stock after Q2 beat

Needham has reiterated a Hold rating on Zimmer Biomet Holdings Inc. (NYSE:ZBH) after the medical device company surpassed second-quarter revenue and EPS expectations. Despite strong gross profit margins and anticipated net income growth, the firm maintains its Hold rating due to expected challenges in …

AC Immune (NASDAQ:ACIU) Announces Earnings Results, Misses Estimates By $0.09 EPS

Immuneering (NASDAQ:IMRX) Releases Earnings Results

Zimmer Biomet Holdings Releases Q2 2026 Financial Results

Zimmer Biomet Holdings reported strong Q2 2026 financial results, surpassing Wall Street expectations with adjusted earnings of $2.07 per share and revenue of $2.18 billion. The medical technology company showed consistent growth across its product lines and provided a full-year adjusted EPS projection of …

Laurion Capital discloses 6.06% Immunic (IMUX) stake via shares and warrants

Laurion Capital Management LP and its related entities have disclosed a 6.06% beneficial ownership stake in Immunic, Inc. (IMUX) as of June 30, 2026. This stake comprises 839,526 shares, including common stock and shares issuable upon the exercise of warrants. The filing indicates shared …

Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook

Zimmer Biomet has reported Q2 revenues of around $2.18bn, denoting a year-over-year (YoY) uptick of 4.8%, and a revised full year outlook. Zimmer's knees segment was its strongest performer in Q2, with sales totalling $828.9m, followed by S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and …

Immunocore set to report earnings ahead of pivotal trial data

Immunocore Holdings PLC is set to report second-quarter financial results with investors focusing on the commercial performance of its drug KIMMTRAK and the progress of its clinical trial for cutaneous melanoma. Analysts anticipate earnings of $0.01 per share on $110.3 million in revenue. The …

Immunocore Q2 2026 Earnings Preview

* Immunocore (IMCR [https://seekingalpha.com/symbol/IMCR]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is $0.02 [https://seekingalpha.com/symbol/IMCR/earnings/estimates] (+110.0% Y/Y) and the consensus Revenue Estimate is $110.37M (+12.6% Y/Y). * Over the last 3 months, EPS …

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio IBRX reported an adjusted loss of 8 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 9 cents. The loss improved 20% compared with the year-ago period's loss of 10 cents. Total revenues …

[ZBH Q2 2026 Earnings Call] Zimmer Biomet Beats and Raises as Hip, Tech Sales Surge; U.S. Technology Revenue Jumps 53%

Zimmer Biomet exceeded Q2 2026 expectations, driven by strong hip and technology sales, leading to a raised full-year guidance. The company reported a 4.8% increase in net sales and a 53% jump in U.S. technology revenue, alongside significant growth in hip sales. CEO Iván …

Earnings call transcript: Zimmer Biomet lifts 2026 outlook after Q2 beat

Zimmer Biomet (ZBH) reported strong second-quarter 2026 results, beating Wall Street expectations for both earnings and revenue, leading the company to raise its full-year 2026 outlook. The orthopedic-device maker saw significant growth in hip sales, technology and data, and its S.E.T. business, with its …

Immunocore Holdings PLC Sponsored ADR $IMCR Position Boosted by Janus Henderson Group PLC

Janus Henderson Group PLC increased its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) by 30.9% in the first quarter, now owning 594,712 shares worth $17.9 million. Several other institutional investors also adjusted their positions, with institutional investors and hedge funds collectively owning 84.5% …

Transcript : Zimmer Biomet Holdings, Inc., Q2 2026 Earnings Call, Aug 05, 2026

This article provides the transcript of Zimmer Biomet Holdings, Inc.'s Q2 2026 Earnings Call from August 5, 2026. The content is primarily a record of the conference call proceedings, including the operator's message and an invitation for subscribers to access the full transcript. The …

Zimmer (ZBH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zimmer Biomet (ZBH) reported $2.18 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 4.8%. EPS of $2.07 for the same period compares to $2.07 a year ago. The reported revenue represents a surprise of +2.25% over the Zacks …

AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances across pipeline, with further near-term clinical results anticipated for H2 2026Phase 2 VacSYn trial of ACI-7104 in Parkinson’s …

Zimmer Biomet raises full-year outlook after second-quarter earnings beat

Researcher looking through microscope ©Adobe Stock Images Zimmer Biomet Holdings (NYSE:ZBH) reported better-than-expected second-quarter results and increased its guidance for the full year, helping lift the medical technology company's shares more than 4% in pre-market trading. The company posted adjusted earnings of $2.07 per …

Altimmune to discuss its liver-treatment candidate Aug. 12

Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026, including a conference call and webcast at 8:30 a.m. ET to review results and provide a business update. The company is a late clinical-stage biopharmaceutical company developing pemvidutide …

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune, Inc. (Nasdaq: ALT) announced it will report its second quarter 2026 financial results and provide a business update on Wednesday, August 12, 2026. Management will host a conference call at 8:30 a.m. ET to discuss the results and update, which will also be …

AC Immune: Q2 Earnings Snapshot

Zimmer Biomet stock rises 4% on Q2 beats, raised guidance By Investing.com

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) reported stronger-than-expected second-quarter results and subsequently raised its full-year guidance, leading to a 4.27% increase in pre-market trading. The medical technology company surpassed analyst consensus for both adjusted earnings per share and revenue. This positive performance was attributed to …